Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hepburn, T. W.
Right arrow Articles by Davis, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hepburn, T. W.
Right arrow Articles by Davis, C. B.
Related Collections
Right arrow Education
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 54-61
© 2003 British Society for Rheumatology

Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis

T. W. Hepburn, M. C. Totoritis1 and C. B. Davis

Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, King of Prussia, PA and
1 IDEC Pharmaceuticals, San Diego, CA, USA

Objective. Keliximab studies have provided evidence of the therapeutic potential of a non-depleting CD4 monoclonal antibody (mAb) in the treatment of rheumatoid arthritis (RA). Clenoliximab, an immunoglobulin G4 derivative of keliximab, has substantially reduced potential to deplete CD4 cells. In initial studies of clenoliximab, we investigated the hypothesis that the decrease in cell surface CD4 is the result of antibody-mediated stripping from the cell surface.

Methods. Patients received single or multiple intravenous infusions of clenoliximab as follows: 0.05, 0.2, 1, 5, 10 or 15 mg/kg (n=3–5/group); 150 or 350 mg weeklyx4; or 350 or 700 mg every other weekx2 (n=12/group). Blood was collected for up to 16 weeks and pharmacokinetic and pharmacodynamic assessments were conducted using immunoassay and flow cytometry.

Results. CD4 count was largely unaffected by clenoliximab treatment. Dose-dependent CD4 coating, down-modulation and stripping were observed. Maximal down-modulation persisted for an increasing period as dose increased, while soluble CD4–clenoliximab complexes accumulated. The amount of CD4 in soluble complex was as much as 20 times the amount of cell-associated CD4. For the same total dose, administration of higher doses, less frequently, resulted in pharmacodynamic profiles similar to those of lower doses administered more frequently.

Conclusion. Decrease in the density of CD4 on the T-lymphocyte surface is caused by antibody-mediated stripping.

KEY WORDS: CD4, Monoclonal antibodies, Pharmacokinetics, Pharmacodynamics, Receptor stripping, Rheumatoid arthritis, T cell.

Correspondence to: T. W. Hepburn, GlaxoSmithKline, Department of Drug Metabolism and Pharmacokinetics, 709 Swedeland Road, PO Box 1539 (UW2720), King of Prussia, PA 19406, USA. E-mail: timothy_w_hepburn{at}gsk.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 QJMHome page
A.W. Morgan, G. Hale, P.R.U.B. Rebello, S.J. Richards, H.-C. Gooi, H. Waldmann, P. Emery, and J.D. Isaacs
A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis
QJM, April 1, 2008; 101(4): 299 - 306.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. A. Little, G. Bhangal, C. L. Smyth, M. T. Nakada, H. T. Cook, S. Nourshargh, and C. D. Pusey
Therapeutic Effect of Anti-TNF-{alpha} Antibodies in an Experimental Model of Anti-Neutrophil Cytoplasm Antibody-Associated Systemic Vasculitis
J. Am. Soc. Nephrol., January 1, 2006; 17(1): 160 - 169.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.